L-162537
L-162537 is a competitive human angiotensin II receptor 1 (AT1) and receptor 2 (AT2) antagonist with an IC50=1.7 nM for AT1. L-162537 inhibits Ang II-mediated vasoconstriction, blood pressure elevation and related pathological signaling pathways. L-162537 is promising for research of angiotensin II-related cardiovascular diseases such as hypertension.
For research use only. We do not sell to patients.
- CAS No.: 167027-99-8
- Formula: C38H32N8O2
- Molecular Weight:632.71
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Angiotensin Receptor Isoforms
More
Biological Activity
Description
IC50 & Target
|
AT1 Receptor 1.7 nM (IC50) |
AT2 Receptor |
Chemical Information
-
CAS No. 167027-99-8
-
Molecular Weight 632.71
-
Formula C38H32N8O2
-
SMILES
CCCC1=NC2=C(C(N1CC3=CC=C(C4=C(C5=NNN=N5)C=CC=C4)C=C3)=O)C=C(N(CC6=CN=CC=C6)C(C7=CC=CC=C7)=O)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)